Based on the Chinese guidelines, and promising results of relevant previous studies, we conducted the present study to compare the efficacy and safety of RBV plus IFN-α, LPV/r plus IFN-α, and RBV plus LPV/r plus IFN-α in patients with mild to moderate COVID-19. The gene discussed is IFNA1; the disease is COVID-19.